RecruitingRecruiting
Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance
NCT07278362 · University of Miami
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Safety of Intramuscular Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance
About this study
The purpose of this study is evaluate the safety of testosterone replacement therapy in men with newly diagnosed low-risk prostate cancer and hypogonadism on active surveillance.
Eligibility criteria
Inclusion Criteria:
* Males aged ≥ 18 years old
* Newly diagnosed with low-risk prostate cancer initially confirmed by fusion guided prostate biopsy (transrectal or trans perineal) by multiparametric MRI
* Males diagnosed with low-risk prostate cancer on active surveillance
* Two confirmatory testosterone levels \<350 ng/dL (taken before 10am), with at least 24 hours and no more than 90 days between the two tests
* Symptoms of low testosterone (Aging Male's Symptoms Score \>27)
* Able to obtain Testosterone medication through insurance or out-of-pocket
* Willing and able to provide written informed consent and able to comply with study requirements
Exclusion Criteria:
* Males \<18 years old
* History of Testosterone Replacement Therapy (TRT) within the past year.
* Current use of TRT
* Diagnosis of Gleason score 7 (Grade Group 2) prostate cancer or higher on diagnostic or confirmatory biopsy
* PSA \>10 ng/mL at baseline
* Hematocrit \> 51% at baseline
* T3 or T4 disease
* Unstable angina
* History of breast cancer
* Any other condition or situation which, in the opinion of the investigator, could impact patient safety, prevent successful data collection, or reduce the likelihood of successful study participation
* Unable or unwilling to obtain Testosterone medication through insurance or out-of-pocket
* Unable or unwilling to provide informed consent or comply with study requirements
Study design
Enrollment target: 35 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-11-30
Estimated completion: 2032-05-31
Last updated: 2026-11-02
Interventions
Drug: Testosterone cypionate
Primary outcomes
- • Proportion of Participants with Disease Progression Within 12 Months After Initiating TRT (12 months)
Sponsor
University of Miami · other
Contacts & investigators
ContactBruce Kava, MD · contact · bkava@med.miami.edu · 305-243-6590
ContactLaura Angulo Llanos · contact · lxa2084@med.miami.edu · 305-243-4850
InvestigatorBruce Kava, MD · principal_investigator, University of Miami
All locations (2)
Desai Sethi Urology InstituteRecruiting
Miami, Florida, United States
Sylvester Comprehensive Cancer CenterRecruiting
Miami, Florida, United States